With the emergence of antibody-drug conjugates, the genitourinary cancers space is rapidly evolving. Dr Ferris addresses ...
When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...
The MarketWatch News Department was not involved in the creation of this content. FCS Physicians Present Novel Clinical Trial Findings in Prostate and Urothelial Cancers at the ASCO 2026 Genitourinary ...
This study leverages CDC National Health Interview Survey data to examine financial distress (FD) among genitourinary (GU) cancer survivors, specifically prostate cancer (PC), kidney cancer (KC), and ...
Cross-referencing protocols/registries with publications revealed substantial attrition from planned QoL endpoints to disseminated results across prostate, kidney, and bladder cancer trials. Selective ...
Contemporary outcomes of nephrectomy with IVC thrombectomy: Analysis from a large multi-institutional database. Metastatic progression and toxicity in high-risk clear cell renal cell carcinoma ...
The evolution of genitourinary cancer treatment includes a shift from monotherapies to combination therapies, improving survival and quality of life. Combining androgen blockers with DNA repair ...
Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor. Tanya B. Dorff, MD, medical oncologist and ...
Family awareness of genetic risk in affected Caucasian ancestry members with bladder cancer (BC) associated with germline variants in DNA‐repair genes (gDRGs). Artificial intelligence in the diagnosis ...
Enfortumab vedotin and pembrolizumab combination shows a 49% reduction in mortality risk for advanced bladder cancer compared to chemotherapy. ASCO GU symposium focuses on antibody-drug conjugates, ...
Cancer is not an outside invader but a biological process, explains Dr. Alexandra Drakaki, medical director of the ...
FORT MYERS, Fla., Feb. 26, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute, LLC (FCS) advances genitourinary cancer treatment through participation at the global ASCO® 2026 ...